CSIMarket Company Name, Ticker, Competitors, else..
 
Pulmatrix Inc   (NASDAQ: PULM)
Other Ticker:  
 
 
Price: $6.3170 $0.77 13.820%
Day's High: $6.5 Week Perf: 16.98 %
Day's Low: $ 5.60 30 Day Perf: -18.17 %
Volume (M): 8 52 Wk High: $ 10.40
Volume (M$): $ 51 52 Wk Avg: $4.00
Open: $5.60 52 Wk Low: $1.72



 Market Capitalization (Millions $) 23
 Shares Outstanding (Millions) 4
 Employees 13
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Pulmatrix Inc
Pulmatrix Inc is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutics for respiratory and pulmonary diseases. The company utilizes its proprietary technology platform, called iSPERSE, to deliver drug candidates directly to the lungs, improving their effectiveness and minimizing systemic side effects. Pulmatrix focuses on developing treatments for chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions. The company's goal is to improve the quality of life for patients suffering from these diseases by providing innovative and targeted therapies.


   Company Address: 945 Concord Street Framingham 1701 MA
   Company Phone Number: 355-4440   Stock Exchange / Ticker: NASDAQ PULM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.92%    
JNJ        3.78% 
LLY        14.68% 
MRK   -1.49%    
SNY   -1.19%    
TEVA        3.82% 
• View Complete Report
   



Pulmatrix Inc

Pulmatrix Inc Surpasses Expectations with Revenue Surge and Profit Growth in Q1 20242.

Pulmatrix Inc Presents Strong First Quarter Performance in Face of Struggling Pharmaceutical Sector
Following an astounding revenue rise of 292.595% year on year to $5.89 million in its Mar 31 2024 report, Pulmatrix Inc has reported positive profits at $0.23 per share. The company's success comes at a time when many businesses in the Major Pharmaceutical Preparations sectors are grappling with declining orders and diminishing revenue.
Compared to the previous reporting period where earnings per share stood at $0.00 and revenue was recorded at $2.20 million, Pulmatrix Inc has doubled its revenue by 167.257%. Moreover, the company has achieved a bottom-line profit of $0.825 million in the first quarter of the 2024 earnings season, marking a significant improvement over the net deficit of $-4.448 million in the same period the previous year.
Pulmatrix Inc

Pulmatrix Inc. Reports Revenue Surge in Fourth Quarter of 2023, But Profits Remain Elusive

Despite a surge in revenue, Pulmatrix Inc (PULM) reported a lack of profitability in the fourth quarter of 2023. The company's profitability reached zero at $0.00 per share, which is disappointing news for investors.
However, there is some positive growth to note. PULM's revenue jumped by an impressive 28.923% to $2.20 million compared to the same reporting period a year prior. Additionally, compared to the previous quarter, revenue improved by 25.613%, moving from $1.75 million. This indicates a healthy demand landscape for PULM solutions, despite the persistently challenging supply side. The company is focused on navigating this environment to catch up with promises and deliver on next period business objectives.






Pulmatrix Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com